Assessment of global myocardial perfusion reserve using cardiovascular magnetic resonance of coronary sinus flow at 3 Tesla

Journal of Cardiovascular Magnetic Resonance

Afshin Farzaneh-Far²  Rosalia C Gonzalez¹  Carolyn Dickens¹  Andrew W Ertel³  Michael A Bauml¹  Vineet K Dandekar¹ 

[1] Section of Cardiology, Department of Medicine, University of Illinois at Chicago, 840 South Wood St. M/C 715, Suite 920 S, Chicago, IL 60612, USA;Division of Cardiology, Department of Medicine, Duke University, Durham, NC, USA;National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda MD, USA

关键词: Regadenoson;    Perfusion;    Stress testing;    Cardiovascular magnetic resonance;   

Others  :  801529
DOI  :  10.1186/1532-429X-16-24

 received in 2013-11-19, accepted in 2014-03-03,  发布年份 2014

【 摘 要 】

Background

Despite increasing clinical use, there is limited data regarding regadenoson in stress perfusion cardiovascular magnetic resonance (CMR). In particular, given its long half-life the optimal stress protocol remains unclear. Although Myocardial Perfusion Reserve (MPR) may provide additive prognostic information, current techniques for its measurement are cumbersome and challenging for routine clinical practice.

The aims of this study were: 1) To determine the feasibility of MPR quantification during regadenoson stress CMR by measurement of Coronary Sinus (CS) flow; and 2) to investigate the role of aminophylline reversal during regadenoson stress-CMR.

Methods

117 consecutive patients with possible myocardial ischemia were prospectively enrolled. Perfusion imaging was performed at 1 minute and 15 minutes after administration of 0.4 mg regadenoson. A subgroup of 41 patients was given aminophylline (100 mg) after stress images were acquired. CS flow was measured using phase-contrast imaging at baseline (pre CS flow), and immediately after the stress (peak CS flow) and rest (post CS flow) perfusion images.

Results

CS flow measurements were obtained in 92% of patients with no adverse events. MPR was significantly underestimated when calculated as peak CS flow/post CS flow as compared to peak CS flow/pre CS flow (2.43 ± 0.20 vs. 3.28 ± 0.32, p = 0.03). This difference was abolished when aminophylline was administered (3.35 ± 0.44 vs. 3.30 ± 0.52, p = 0.95). Impaired MPR (peak CS flow/pre CS flow <2) was associated with advanced age, diabetes, current smoking and higher Framingham risk score.

Conclusions

Regadenoson stress CMR with MPR measurement from CS flow can be successfully performed in most patients. This measurement of MPR appears practical to perform in the clinical setting. Residual hyperemia is still present even 15 minutes after regadenoson administration, at the time of resting-perfusion acquisition, and is completely reversed by aminophylline. Our findings suggest routine aminophylline administration may be required when performing stress CMR with regadenoson.

【 授权许可】

   
2014 Dandekar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, Iskandrian AE: Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. JACC Cardiovasc Imaging 2012, 5(10):1014-1021.
• [2]Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE, Investigators A-MT: Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008, 1(3):307-316.
• [3]Al Jaroudi W, Iskandrian AE: Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 2009, 54(13):1123-1130.
• [4]Bhave NM, Freed BH, Yodwut C, Kolanczyk D, Dill K, Lang RM, Mor-Avi V, Patel AR: Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson. J Cardiovasc Magn Reson 2012, 14:89. BioMed Central Full Text
• [5]DiBella EV, Fluckiger JU, Chen L, Kim TH, Pack NA, Matthews B, Adluru G, Priester T, Kuppahally S, Jiji R, McGann C, Litwin SE: The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study. Int J Cardiovasc Imaging 2012, 28(6):1435-1444.
• [6]Vasu S, Bandettini WP, Hsu LY, Kellman P, Leung S, Mancini C, Shanbhag SM, Wilson J, Booker OJ, Arai AE: Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. Cardiovasc Magn Reson 2013, 15(1):85. BioMed Central Full Text
• [7]Freed BH, Narang A, Bhave NM, Czobor P, Mor-Avi V, Zaran ER, Turner KM, Cavanaugh KP, Chandra S, Tanaka SM, Davidson MH, Lang RM, Patel AR: Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2013, 15:108. BioMed Central Full Text
• [8]Nguyen KL, Bandettini WP, Shanbhag S, Leung SW, Wilson JR, Arai AE: Safety and tolerability of regadenoson CMR. Eur Heart J Cardiovasc Imaging 2014. [Epub ahead of print]
• [9]Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H: A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 2006, 45(12):1201-12.
• [10]Morton G, Chiribiri A, Ishida M, Hussain ST, Schuster A, Indermuehle A, Perera D, Knuuti J, Baker S, Hedstrom E, Schleyer P, O’Doherty M, Barrington S, Nagel E: Quantification of absolute myocardial perfusion in patients with coronary artery disease: comparison between cardiovascular magnetic resonance and positron emission tomography. J Am Coll Cardiol 2012, 60(16):1546-55.
• [11]Schwitter J, DeMarco T, Kneifel S, von Schulthess GK, Jorg MC, Arheden H, Ruhm S, Stumpe K, Buck A, Parmley WW, Luscher TF, Higgins CB: Magnetic Resonance-Based Assessment of Global Coronary Flow and Flow Reserve and Its Relation to Left Ventricular Functional Parameters: a Comparison With Positron Emission Tomography. Circulation 2000, 101(23):2696-702.
• [12]Hutchins GD, Schwaiger M, Rosenspire KC, Krivokapich J, Schelbert H, Kuhl DE: Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging. J Am Coll Cardiol 1990, 15(5):1032-42.
• [13]Murthy VL, Di Carli MF: Non-invasive quantification of coronary vascular dysfunction for diagnosis and management of coronary artery disease. J Nucl Cardiol 2012, 19(5):1060-72. quiz 1075
• [14]Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, Blankstein R, Dorbala S, Sitek A, Pencina MJ, Di Carli MF: Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation 2011, 124(20):2215-24.
• [15]Herzog BA, Husmann L, Valenta I, Gaemperli O, Siegrist PT, Tay FM, Burkhard N, Wyss CA, Kaufmann PA: Long-term prognostic value of 13 N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. J Am Coll Cardiol 2009, 54(2):150-6.
• [16]Tio RA, Dabeshlim A, Siebelink HM, de Sutter J, Hillege HL, Zeebregts CJ, Dierckx RA, van Veldhuisen DJ, Zijlstra F, Slart RH: Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. Nucl Med 2009, 50(2):214-9.
• [17]Bloch KM, Carlsson M, Arheden H, Stahlberg F: Quantifying coronary sinus flow and global LV perfusion at 3 T. BMC Med Imaging 2009, 9:9. BioMed Central Full Text
• [18]Koskenvuo JW, Hartiala JJ, Knuuti J, Sakuma H, Toikka JO, Komu M, Saraste M, Niemi P: Assessing coronary sinus blood flow in patients with coronary artery disease: a comparison of phase-contrast MR imaging with positron emission tomography. AJR Am J Roentgenol 2001, 177(5):1161-6.
• [19]Hood WB Jr: Regional venous drainage of the human heart. Br Heart J 1968, 30(1):105-9.
• [20]Lund GK, Wendland MF, Shimakawa A, Arheden H, Stahlberg F, Higgins CB, Saeed M: Coronary sinus flow measurement by means of velocity-encoded cine MR imaging: validation by using flow probes in dogs. Radiology 2000, 217(2):487-93.
• [21]Klem I, Heitner JF, Shah DJ, Sketch MH Jr, Behar V, Weinsaft J, Cawley P, Parker M, Elliott M, Judd RM, Kim RJ: Improved detection of coronary artery disease by stress perfusion cardiovascular magnetic resonance with the use of delayed enhancement infarction imaging. J Am Coll Cardiol 2006, 47(8):1630-8.
• [22]Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 1(8476):307-10.
• [23]Koskenvuo JW, Sakuma H, Niemi P, Toikka JO, Knuuti J, Laine H, Komu M, Kormano M, Saraste M, Hartiala JJ: Global myocardial blood flow and global flow reserve measurements by MRI and PET are comparable. Magn Reson Imaging 2001, 13(3):361-6.
• [24]Moro PJ, Flavian A, Jacquier A, Kober F, Quilici J, Gaborit B, Bonnet JL, Moulin G, Cozzone PJ, Bernard M: Gender differences in response to cold pressor test assessed with velocity-encoded cardiovascular magnetic resonance of the coronary sinus. J Cardiovasc Magn Reson 2011, 13:54. BioMed Central Full Text
• [25]Camici PG, Crea F: Coronary microvascular dysfunction. N Engl J Med 2007, 356(8):830-40.
• [26]Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J, Everett CC, Bijsterveld P, Ridgway JP, Radjenovic A, Dickinson CJ, Ball SG, Plein S: Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet 2012, 379(9814):453-60.
• [27]Gerber BL, Raman SV, Nayak K, Epstein FH, Ferreira P, Axel L, Kraitchman DL: Myocardial first-pass perfusion cardiovascular magnetic resonance: history, theory, and current state of the art. J Cardiovasc Magn Reson 2008, 10:18. BioMed Central Full Text
• [28]D’Cruz IA, Shala MB, Johns C: Echocardiography of the coronary sinus in adults. Clin Cardiol 2000, 23(3):149-54.
• [29]Gatehouse PD, Rolf MP, Graves MJ, Hofman MB, Totman J, Werner B, Quest RA, Liu Y, von Spiczak J, Dieringer M, Firmin DN, van Rossum A, Lombardi M, Schwitter J, Schulz-Menger J, Kilner PJ: Flow measurement by cardiovascular magnetic resonance: a multi-centre multi-vendor study of background phase offset errors that can compromise the accuracy of derived regurgitant or shunt flow measurements. Cardiovasc Magn Reson 2010, 12:5. BioMed Central Full Text